Prime Therapeutics Care Specialists program provides clinical guidance, medication education and ongoing support related to specialty therapies

One of the Prime Together Foundation’s 2023 grants went to TC Food Justice, which works to reduce food waste and hunger in the Twin Cities by linking those willing to help and those in need.

New report, an evolution of previous DEI reports, aims to demonstrate transparency and accountability for company’s corporate social responsibility journey

Mahajan brings more than 20 years of global finance and leadership experience across healthcare, pharmacy and financial services organizations

In its annual fall report dedicated to oncology, Prime Therapeutics highlights strategies to improve outcomes, reduce costs and support patients — starting with a bold approach to managing cancer care

New continuing education course showcases her expertise in biomarker testing and targeted therapy for EGFR-mutated NSCLC

Report features new highlights and rankings of the top 50 drug classes by percent of net spend.

Certification recognizes quality service and continuous improvement

Grant helps provide a home away from home for families facing cancer

Payne to integrate communications, government affairs and policy efforts at leading purpose-driven, transparent PBM

How Prime Therapeutics/Magellan Rx Management reimagines pharmacy to do what's right.

The event emphasizes additional measures for obesity therapy.

Prime is committed to simplifying the cancer care journey through leading oncology solutions designed to support people with cancer

Prime Therapeutics helps simplify the cancer care journey and manage drug costs through leading oncology solutions

Prime Therapeutics experts share more about the latest in precision oncology, including barriers to treatment and the current regulatory landscape

Report encourages providers to consider health contexts and lifestyle modifications as well as personal preferences and current guidelines when prescribing GLP-1s for weight loss

At Pharmacy Benefit Management Institute (PBMI) annual conference, Prime received two awards: one for cost savings, another for leadership.

With open enrollment beginning Oct. 15, Prime highlights Medicare offerings that are helping drive greater value and affordability for plan sponsors and patients

Prime Therapeutics/Magellan Rx Management's signature event featured the hottest topics in specialty drug management and more

Magellan Rx first to innovate with Medicaid VBC solutions for states grappling with the high cost of novel cell and gene therapies

Prime Therapeutics is committed to simplifying the patient journey for those with complex conditions through its industry-leading HighTouchRx product

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products

Event features discussions about health care industry trends, best practices and innovations

Formulary design recommendations help create competition to drive savings, provide optionality to meet unique client needs.

Leading GLP-1 persistence, adherence and clinical outcomes research helps inform health plans and members

Studies include Prime’s GLP-1 obesity research, the impact of social determinants of health and more.

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

Prime Therapeutics clinical experts shared insights on the specialty drug pipeline at recent industry event

A look at the specialty landscape and how Prime delivers value to employers

Stories, perspectives and news coverage of Prime Therapeutics/Magellan Rx from AMCP 2024

Prime Therapeutics researchers share how the model helps to optimize drug therapy and lower costs

Table view Editor-in-chief's message Year 2024 2025 2026 2027 2028 Projected Yearly U.S. Sales $0 $82 $177 $258 $311 The pipeline drug list is an aerial outline of drugs with anticipated FDA...

Prime Therapeutics offers innovative medication management solutions, supports patients with chronic conditions

Abby Kim, PharmD, BCOP, senior director of oncology, clinical strategy and specialty solutions at Prime Therapeutics, examines the trends payers should watch as cancer care becomes more complex

Abby Kim, PharmD, BCOP, is a senior director, clinical strategy and oncology specialty solutions, shares key takeaways from the American Journal of Managed Care (AJMC) forum, “Bridging evidence and...

Pat Gleason, assistant vice president, health outcomes, and David Eckwright, senior director, clinical project and program management, share an overview of Prime’s data and insights slated for this...

Prime simplifies the cancer care pathway through innovative solutions that help manage complex conditions

In the latest episode of the “Pharmacy Friends” podcast, hear more about what faster drug decisions could mean for evidence review, affordability assessment and implementation planning

From new treatment options for dry eye disease to type 2 diabetes, here are a few of the top U.S. Food and Drug Administration drug decisions expected this year

Prime works to simplify medication management and support patients with migraine, making migraine treatment less of a pain point

As more and more high-cost therapies, including cell and gene therapies (CGTs), enter the U.S. market, commercial health plans have multiple tools at their disposal to manage these agents

Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting.

Submitted supplemental drugs Phase 3 supplemental drugs arimoclomol oral Name Manufacturer Clinical Use Dosage Form Development Status camrelizumab Jiangsu Hengrui HCC (unresectable, 1st-line, in...

Drug Generic Name Therapeutic category July2024 Pipeline - Total US sales for 2028 (Dollars in millions) botaretigene sparoparvovec Ophthalmology / Gene therapy $158 crinecerfont Endocrine $325...

Dosage and administration In the VISIONARY trial, sibeprenlimab was administered SC at a dose of 400 mg every 4 weeks and can be self-administered. Place in therapy IgAN, also known as Berger’s...

Name Manufacturer Clinical use Dosage form Development status - FDA designations FDA decision aflibercept (Eylea HD) 8 mg Regeneron Macular edema from RVO (8 mg dose) Intravitreal sNDA – PR Oct-Dec...

ensitrelvir - Infectious disease Name Manufacturer Clinical use Dosage form Development status - FDA designations FDA decision oxylanthanum carbonate (Renazorb) Unicycive Hyperphosphatemia (in...

Name Manufacturer Clinical Use Dosage Form Development Status FDA Decision adalimumab-bwwd 40 mg/0.4 mL (Hadlima™) (biosimilar to Abbvie’s Humira®) Organon RA; AS; PSO; PsA; JIA; CD; UC; HS;...

Submitted supplemental drugs brensocatib oral Manufacturer: PTC Proposed indications Friedreich's ataxia (FA) Clinical overview Mechanism of action Vatiquinone is a first-in-class selective...

Manufacturer: Abeona Proposed indications Recessive dystrophic epidermolysis bullosa (RDEB) Clinical overview Mechanism of action Prademagene zamikeracel (pz-cel) is an autologous, collagen type...

Manufacturer: Ferring / Seikagaku Proposed indications Radicular leg pain associated with lumbar disc herniation (LDH) Clinical overview Mechanism of action Condoliase, also known as chondroitin...